?????????????????????????? ??????????????????????????gene in people relapsing after treatment method Using the BCL2 antagonist venetoclax. sixty six Resistance to those agents continues to be associated with these mutations in around 70% of scenarios, Despite the fact that they tend to be subclonal as well as their unique purpose triggering resista